27578983|t|EGFR protein expression using a specific intracellular domain antibody and PTEN and clinical outcomes in squamous cell lung cancer patients with EGFR-tyrosine kinase inhibitor therapy
27578983|a|The aim of this research was to examine the molecular and clinical features that are related with EGFR-tyrosine kinase inhibitor (EGFR-TKI) efficacy in previously treated patients with squamous cell carcinoma of the lung (SCCL). This retrospective study included 67 SCCL patients with obtainable lung cancer tissue and records on EGFR-TKI treatment response and survival. EGFR protein expression in lung cancer tissue was measured by immunohistochemistry with a specific antibody that recognizes the intracellular domain (ID) of EGFR. PTEN expression in lung cancer tissue was also evaluated with immunohistochemistry. PI3KCA gene amplification was detected by quantitative real-time polymerase chain reaction, and FGFR1 amplification was assessed by fluorescent in situ hybridization. EGFR ID expression (hazard ratio [HR] 0.53, P=0.022) and Eastern Cooperative Oncology Group (ECOG) performance status (PS) (HR 0.43, P=0.022) were significantly related with progression - free survival following EGFR-TKIs treatment. PTEN expression (HR 0.52, P=0.025) was significantly related to overall survival. The group of EGFR - positive or PTEN - positive patients with ECOG PS of 0 or 1 had better clinical outcomes than patients who were EGFR - negative and PTEN - negative or who had poor ECOG PS with longer median progression - free survival (2.1 vs 1.0 months, P=0.05) and overall survival (6.2 vs 2.1 months, P=0.05). EGFR expression using an ID -specific antibody and PTEN protein expression may be used to identify SCCL patients who might benefit from EGFR-TKI treatment.
27578983	0	12	EGFR protein	T103	UMLS:C1739039
27578983	13	23	expression	T038	UMLS:C1171362
27578983	41	54	intracellular	T082	UMLS:C0178719
27578983	55	61	domain	T082	UMLS:C1514562
27578983	62	70	antibody	T103	UMLS:C0003241
27578983	75	79	PTEN	T103	UMLS:C1430988
27578983	105	130	squamous cell lung cancer	T038	UMLS:C0149782
27578983	145	183	EGFR-tyrosine kinase inhibitor therapy	T058	UMLS:C3899317
27578983	200	208	research	T062	UMLS:C0035168
27578983	216	223	examine	T058	UMLS:C0582103
27578983	282	312	EGFR-tyrosine kinase inhibitor	T058	UMLS:C3899317
27578983	314	322	EGFR-TKI	T058	UMLS:C3899317
27578983	347	354	treated	T033	UMLS:C0332154
27578983	369	404	squamous cell carcinoma of the lung	T038	UMLS:C0149782
27578983	406	410	SCCL	T038	UMLS:C0149782
27578983	418	437	retrospective study	T062	UMLS:C0035363
27578983	450	454	SCCL	T038	UMLS:C0149782
27578983	480	491	lung cancer	T038	UMLS:C0684249
27578983	492	498	tissue	T017	UMLS:C0040300
27578983	503	510	records	T170	UMLS:C0034869
27578983	514	532	EGFR-TKI treatment	T058	UMLS:C3899317
27578983	556	568	EGFR protein	T103	UMLS:C1739039
27578983	569	579	expression	T038	UMLS:C1171362
27578983	583	594	lung cancer	T038	UMLS:C0684249
27578983	595	601	tissue	T017	UMLS:C0040300
27578983	618	638	immunohistochemistry	T058	UMLS:C0021044
27578983	655	663	antibody	T103	UMLS:C0003241
27578983	669	679	recognizes	T038	UMLS:C0524637
27578983	684	697	intracellular	T082	UMLS:C0178719
27578983	698	704	domain	T082	UMLS:C1514562
27578983	706	708	ID	T082	UMLS:C1514562
27578983	713	717	EGFR	T103	UMLS:C1739039
27578983	719	723	PTEN	T103	UMLS:C1430988
27578983	724	734	expression	T038	UMLS:C1171362
27578983	738	749	lung cancer	T038	UMLS:C0684249
27578983	750	756	tissue	T017	UMLS:C0040300
27578983	766	775	evaluated	T058	UMLS:C0220825
27578983	781	801	immunohistochemistry	T058	UMLS:C0021044
27578983	803	828	PI3KCA gene amplification	T038	UMLS:C3273085
27578983	833	841	detected	T033	UMLS:C0442726
27578983	845	893	quantitative real-time polymerase chain reaction	T062	UMLS:C3179034
27578983	899	918	FGFR1 amplification	T038	UMLS:C1517090
27578983	935	968	fluorescent in situ hybridization	T062	UMLS:C0162789
27578983	970	974	EGFR	T103	UMLS:C1739039
27578983	975	977	ID	T082	UMLS:C1514562
27578983	978	988	expression	T038	UMLS:C1171362
27578983	1027	1092	Eastern Cooperative Oncology Group (ECOG) performance status (PS)	T201	UMLS:C1520224
27578983	1144	1155	progression	T038	UMLS:C0178874
27578983	1182	1201	EGFR-TKIs treatment	T058	UMLS:C3899317
27578983	1203	1207	PTEN	T103	UMLS:C1430988
27578983	1208	1218	expression	T038	UMLS:C1171362
27578983	1298	1302	EGFR	T103	UMLS:C1739039
27578983	1305	1313	positive	T033	UMLS:C1446409
27578983	1317	1321	PTEN	T103	UMLS:C1430988
27578983	1324	1332	positive	T033	UMLS:C1446409
27578983	1347	1354	ECOG PS	T201	UMLS:C1520224
27578983	1369	1393	better clinical outcomes	T033	UMLS:C1333602
27578983	1417	1421	EGFR	T103	UMLS:C1739039
27578983	1424	1432	negative	T033	UMLS:C0205160
27578983	1437	1441	PTEN	T103	UMLS:C1430988
27578983	1444	1452	negative	T033	UMLS:C0205160
27578983	1469	1476	ECOG PS	T201	UMLS:C1520224
27578983	1496	1507	progression	T038	UMLS:C0178874
27578983	1602	1606	EGFR	T103	UMLS:C1739039
27578983	1607	1617	expression	T038	UMLS:C1171362
27578983	1627	1629	ID	T082	UMLS:C1514562
27578983	1640	1648	antibody	T103	UMLS:C0003241
27578983	1653	1665	PTEN protein	T103	UMLS:C1430988
27578983	1666	1676	expression	T038	UMLS:C1171362
27578983	1701	1705	SCCL	T038	UMLS:C0149782
27578983	1738	1756	EGFR-TKI treatment	T058	UMLS:C3899317